EGFR+ Lung Cancer

>

Latest News

FDA Approval Sought for Dato-DXd in EGFR-Mutated NSCLC
FDA Approval Sought for Dato-DXd in EGFR-Mutated NSCLC

November 14th 2024

A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from multiple TROPION trials, following FDA feedback.

FDA Clears Amivantamab/Chemotherapy Combo in EGFR-Mutant NSCLC
FDA Clears Amivantamab/Chemotherapy Combo in EGFR-Mutant NSCLC

September 20th 2024

Zipalertinib Shows Promise in Heavily Pretreated EGFR Exon 20-Mutated NSCLC
Zipalertinib Shows Promise in Heavily Pretreated EGFR Exon 20-Mutated NSCLC

September 14th 2024

Dexamethasone Prophylaxis Reduces IRRs in Amivantamab Treatment
Dexamethasone Prophylaxis Reduces IRRs in Amivantamab Treatment

September 11th 2024

Amivantamab/Lazertinib Shows Potential in Atypical EGFR-Mutant Lung Cancer
Amivantamab/Lazertinib Shows Potential in Atypical EGFR-Mutant Lung Cancer

August 20th 2024

More News